K&G Techlaw Partners
  • Home
  • Practice Areas
  • Our Teams
  • Blogs
  • Contact
  • Home
  • Practice
  • Intellectual Property Litigation

Intellectual Property Litigation

  • August 19, 2023
  • KngTechLaw
  • 0 Comments

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent Posts

  • Scientific Promotion of Pharmaceuticals Products in India
  • THE REGULATORY FILING MA FOR FORMULATIONS IN THE EU
  • THE ENVIRONMENTAL, SOCIAL, AND GOVERNANCE (ESG) Understanding and Mitigating the Risk
  • The Doctrine of Equivalency Explained and Upheld
  • Compliance Requirements for Single-Use Plastic Guidelines

Recent Comments

No comments to show.

Archives

  • July 2023

Categories

  • Blog

Recent post

  • Scientific Promotion of Pharmaceuticals Products in India
    July 17, 2023
  • THE REGULATORY FILING MA FOR FORMULATIONS IN THE EU
    July 17, 2023
  • THE ENVIRONMENTAL, SOCIAL, AND GOVERNANCE (ESG) Understanding and Mitigating the Risk
    July 16, 2023
  • The Doctrine of Equivalency Explained and Upheld
    July 16, 2023

Archives

  • July 2023 (37)

Categories

  • Blog (37)

Tags

14 FDCs prohibited. 2016 2023 Accessibility Guidelines Across Health Sector for Persons with Disabilities ADVISORY ON DIGITAL PRESCRIPTION Artificial Intelligence in Healthcare Industry: ICMR Guidelines COMPLIANCE FOR WHOLESALERS AND PACKERS UNDER LEGAL METROLOGY (PACKAGED COMMODITY) RULES 2011 Compliance Requirements for Single-Use Plastic Guidelines Dark Patterns Compliance DATA PROTECTION BILL COMPLIANCE Don’t Miss the Bus - EBA Guidelines and compulsory implementation E-commerce Guidelines ON ONDC ESG E SHOP SHIPING CHARGE ON SALE OF DRUGS HIV Testing Laws and Compliances K&G Global presence KEY FEATURES OF THE RIGHTS OF PERSONS WITH DISABILITIES ACT Legal Article on Advertisement of drugs MEIT REPORT OF COMMITTEE - B ON LEVERAGING AI FOR IDENTIFYING NATIONAL MISSIONS IN KEY SECTORS OTC Drugs Patent PLANNING TO INTRODUCE SEXUAL WELLNESS TOYS Privacy Policy Recommendations for E-Pharmacy Promotion of Drugs in India QR CODE AND ANTI-COUNTERFEIT MEASURES Registration of Medical Practitioners and Licence to Practice Medicine Regulations REPACKING OF DRUGS SOFTWARE AS A MEDICAL DEVICE - REGULATORY COMPLIANCES The sale of H1 Drugs by E-pharmacy site on the basis of a Narcotics License Track & Trace for Pharmaceutical Products compliance Uniform Code for Medical Device Marketing Practices Voluntary Code of Conduct for E-Pharmacies in India Whether one can sell and deliver cut-strip medicine in India?
Design and Develop by Ovatheme

Terms of Use and our Privacy Policy

Under the rules of the Bar Council of India, K&G Techlaw Partners (the “Firm”) is prohibited from soliciting work or advertising.
By clicking, “I Agree” below, the user acknowledges that:

  1. There has been no advertisement, personal communication, solicitation, invitation or inducement of any sort whatsoever from the Firm or any of its members to solicit any work or advertise through this website
  2. The purpose of this website is to provide the user with information about the Firm, its practice areas, its advocates and solicitors;
  3. The user wishes to gain more information about the Firm for his/her own information and personal/ professional use; and
  4. The information about the Firm is provided to the user only on his/ her specific request and any information obtained or materials downloaded from this website are completely at the user’s volition and any transmission, receipt or use of this website would not create any lawyer-client relationship.
  5. This website is not intended to be a source of advertising or solicitation and the contents hereof should not be construed as legal advice in any manner whatsoever.
  6. The Firm is not liable for any consequence of any action taken by the user relying on material/ information provided under this website. In cases where the user requires any assistance, he/she must seek independent legal advice.
  7. The content of this website is the Intellectual Property of the Firm.

Please read and accept our website’s Terms of Use and our Privacy Policy

This will close in 0 seconds